Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence

Autor: Touko Inao, Tadahiko Shien, Akiko Ogiya, Norikazu Masuda, Masato Takahashi, Naoko Ishida, Hiroyuki Yasojima, Mitsuchika Hosoda, Kieko Yamazaki, Yoshiya Horimoto, Yuichiro Miyoshi, Hiroko Yamashita, Hiroyoshi Doihara, Rie Horii, Tomofumi Osako, Shinichiro Miyoshi, Yumi Endo, Nobumoto Tomioka
Rok vydání: 2016
Předmět:
Adult
0301 basic medicine
Oncology
medicine.medical_specialty
Time Factors
Receptor
ErbB-2
medicine.medical_treatment
Gene Expression
Estrogen receptor
Breast Neoplasms
Biology
Aldehyde Dehydrogenase 1 Family
03 medical and health sciences
Breast cancer
0302 clinical medicine
Cancer stem cell
Surgical oncology
Internal medicine
Biomarkers
Tumor
medicine
Humans
Neoplasm Metastasis
Estrogen receptor-positive
Lymph node
Aged
Medicine(all)
Univariate analysis
Chemotherapy
Retinal Dehydrogenase
Cancer
Middle Aged
Prognosis
medicine.disease
Immunohistochemistry
Isoenzymes
030104 developmental biology
medicine.anatomical_structure
Human epidermal growth factor receptor type 2-negative
Receptors
Estrogen
Aldehyde dehydrogenase 1
030220 oncology & carcinogenesis
Time of recurrence
Neoplastic Stem Cells
Female
Neoplasm Recurrence
Local
Research Article
Follow-Up Studies
Zdroj: Breast Cancer Research : BCR
ISSN: 1465-542X
DOI: 10.1186/s13058-016-0731-3
Popis: Background The significance of the expression of aldehyde dehydrogenase 1 (ALDH1), a cancer stem cell marker, for predicting the recurrence of estrogen receptor (ER)-positive/human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is still poorly understood. The value of ALDH1 in predicting the time of recurrence remains unknown. Methods In total, 184 patients with early distant recurrence, 134 patients with late distant recurrence, and 321 control patients without recurrence for more than 10 years after starting initial treatment for ER-positive/HER2-negative breast cancer, registered in 9 institutions, were analyzed. We assessed relationships between ALDH1 and other clinicopathological features, and ALDH1 expression was compared among the three groups. The relationship between ALDH1 expression and overall survival after recurrence was also evaluated in each group. Results The rates of ALDH1 expression positivity (more than 1 %) in the early, late, and no recurrence groups were 18.4 %, 13.4 %, and 8.4 %, respectively. ALDH1 expression correlated significantly with lymph node metastases (p = 0.048) and the Ki-67 labeling index (p
Databáze: OpenAIRE
Externí odkaz: